Cat. No. 5056
Chemical Name: 3-[[[4-[4-[[[1-(2-Chlorophenyl)etho
Biological ActivityAntagonist of the lysophosphatidic acid receptors LPA1 and LPA3 (Ki values are 0.25 and 0.36 μM respectively, in a GTPγS binding assay). Blocks LPA-induced dephosphorylation of Yes-associated protein (YAP) and WW domain-containing transcription regulator protein 1 (TAZ), inhibiting the Hippo signaling pathway, in HEK293A cells.
The technical data provided above is for guidance only. For batch specific data refer to the Certificate of Analysis.
All Tocris products are intended for laboratory research use only.
Certificate of Analysis / Product Datasheet / Safety Datasheet
References are publications that support the products' biological activity.
Yu et al (2012) Regulation of the Hippo-YAP pathway by G-protein-coupled receptor signaling. Cell 150 780. PMID: 22863277.
Yamada et al (2004) Lysophosphatidic acid (LPA) in malignant ascites stimulates motility of human pancreatic cancer cells through LPA1. J.Biol.Chem. 279 6595. PMID: 14660630.
Ohta et al (2003) Ki16425, a subtype-selective antagonist for EDG-family lysophosphatidic acid receptors. Mol.Pharmacol. 64 994. PMID: 14500756.
If you know of a relevant reference for Ki 16425 please let us know.
Citations are publications that use Tocris products. Selected citations for Ki 16425 include:
Evseenko et al (2013) Lysophosphatidic acid mediates myeloid differentiation within the human bone marrow microenvironment. PLoS One 8 e63718. PMID: 23696850.
Do you know of a great paper that uses Ki 16425 from Tocris? If so please let us know.
View Related Products by Target
View Related Products by Product Action
Keywords: Ki 16425, supplier, Ki16425, lysophosphatidic, acid, receptors, LPA1, LPA2, LPA3, YAP, TAZ, HIPPO, Tocris Bioscience, Lysophosphatidic Acid Receptor Antagonist products
Find multiple products by catalog number
New Products in this Area
Highly potent P2Y12 antagonistFTY 720
Potent S1P receptor agonist; also immunosuppressantCinacalcet hydrochloride
Calcium-sensing receptor (CaSR) allosteric agonist; also CYP2D2 inhibitor and Ca2+ channel blocker; orally bioavailableAMG 837 hemicalcium salt
Potent free fatty acid receptor 1 (FFA1/GPR40) partial agonistUMB 68
GHB receptor ligandAZD 1283
High affinity P2Y12 antagonistEx 26
Potent and selective S1P1 receptor antagonist
Follow Tocris on LinkedIn
Visit our LinkedIn page for the latest Tocris news, events and updates.